Hemostatic alterations in sickle cell disease: Relationships to disease pathophysiology

Pediatric Pathology and Molecular Medicine

Volumn 20, Issue 1, 2001, Pages 27-46

  Stuart, M J ^a   Setty, B N Y ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Anticoagulants; Coagulation hemostasis; Platelets; Sickle cell disease

Indexed keywords

FIBRIN; HEMOGLOBIN S; THROMBIN; MEMBRANE LIPID; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY;

BETA THALASSEMIA; BLOOD CLOTTING; ENDOTHELIUM CELL; ERYTHROCYTE ADHESIVENESS; ERYTHROCYTE MEMBRANE; ERYTHROCYTE SHAPE; FIBRINOLYSIS; GENE MUTATION; HEMOSTASIS; HUMAN; IMMUNOPATHOGENESIS; KNOCKOUT MOUSE; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; THROMBOCYTE; THROMBOGENESIS; THROMBOSIS; ANIMAL; BIOSYNTHESIS; BLOOD; CELL ADHESION; DISEASE MODEL; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE DISORDER; GENETICS; HEMOGLOBINOPATHY; IMMUNOLOGY; INJURY; MOUSE; MOUSE MUTANT; PATHOLOGY; THROMBOCYTE ACTIVATION; THROMBOPHILIA; VASCULAR ENDOTHELIUM;

ANEMIA, SICKLE CELL; ANIMAL; ANTIBODIES, ANTIPHOSPHOLIPID; BETA-THALASSEMIA; CELL ADHESION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE MEMBRANE; ERYTHROCYTES, ABNORMAL; FIBRINOLYSIS; HEMOGLOBINOPATHIES; HUMAN; MEMBRANE LIPIDS; MICE; MICE, KNOCKOUT; PHOSPHATIDYLSERINES; PLATELET ACTIVATION; SUPPORT, U.S. GOV'T, P.H.S.; THROMBIN; THROMBOPHILIA; THROMBOSIS;

EID: 0035113766     PISSN: 15227952     EISSN: None     Source Type: Journal    
DOI: 10.1080/15227950150502529     Document Type: Review

References (141)

1. Pathogenesis and treatment of sickle cell disease
2. Occlusion of large cerebral vessels in sickle cell anemia
3. Cerebrovascular disease in sickle cell anemia: A clinical, pathological, and radiological correlation
4. Cerebrovascular accidents in sickle cell disease: Rates and risk factors
5. Pulmonary changes in sickle cell disease
6. The lung in sickle cell disease
7. Vascular occlusion in sickle cell disease. Current concepts and unanswered questions
8. Renal angiography in sickle cell disease
9. Endothelial cell and vascular damage in the sickle cell disorders
10. Ophthalmologic complications in sickle cell disease
11. Prophylactic red cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study
12. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells: A review
13. Erythrocyte membrane lipid reorganization during the sickling process
14. Uncoupling of the membrane skeleton from the lipid bilayer. The cause of accelerated phospholipid flip-flop leading to an enhanced procoagulant activity of sickled cells
15. Loss of membrane phospholipid asymmetry during activation of blood platelets and sickled red cells. Mechanism and physiologic significance
16. Measurement of membrane phospholipid asymmetry in normal and sickle erythrocytes by means of annexin V binding
17. Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V
18. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: Flow-cytometric measurement and clinical associations
19. Transbilayer movement of phospholipids in red cell and platelet membranes
20. Asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: Relation to shape changes
21. Maintenance and consequences of membrane phospholipid asymmetry
22. Measurement of outward translocation of phospholipids across human erythrocyte membrane
23. Bidirectional transbilayer movement of phospholipid analogs in human red blood cells
24. Role of translocases in the generation of phosphatidylserine asymmetry
25. Mechanism and function of changes in membrane phospholipid asymmetry in platelets and erythrocytes
26. Phosphatidylserine externalization in subpopulations of sickle cells
27. Release of spectrin-free spicules on reoxygenation of sickled erythrocytes
28. Transmembrane mobility of phospholipids in sickle erythrocytes. Effect of deoxygenation on diffusion and asymmetry
29. Red cell membrane remodeling in sickle cell anemia: Sequestration of membrane lipids and proteins in Heinz bodies
30. Oxidative damage does not alter membrane phospholipid asymmetry in human erythrocytes
31. Cation homeostasis
32. Activation of human factor VII in plasma and in purified systems. Roles of activated factor IX, Kallikrein and activated factor XII
33. Tissue factor accelerates the activation of factor VII
34. Factor VII binding to tissue factor in reconstituted phospholipid vesicles. Induction of cooperativity by phosphatidylserine
35. The role of activated human platelets in prothrombin and factor X activation
36. Sickled erythrocytes accelerate clotting in vitro: An effect of abnormal membrane lipid asymmetry
37. Hemostasis in sickle cell disease
38. Coagulation changes during the steady state in homozygous sickle cell disease in Jamaica
39. Is sickle cell crisis a thrombotic event?
40. Fragment D-Dimer levels: An objective marker of vaso-occlusive crisis and other complications of sickle cell disease
41. Elevated fibrin D-dimer fragment in sickle cell anemia: Evidence for activation of coagulation during the steady state as well as in painful crisis
42. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients
43. Enhanced thrombin generation in children with sickle cell disease
44. Prothrombofic changes in children with sickle cell disease: Relationships to cerebrovascular disease and transfusion
45. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease
46. Protein S deficiency in sickle cell anemia
47. Plasma protein C levels in children with sickle cell disease
48. Blood proteins C and S in sickle cell disease
49. Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls
50. Protein C and S in homozygous sickle cell disease
51. Decreased protein S activity in sickle cell disease
52. Antithrombin III concentrate for treatment of chronic leg ulcers in sickle cell-beta thalassemia - A pilot study
53. Antithrombin III deficiency in Nigerian children with sickle cell disease: Possible role in the cerebral syndrome
54. Sickle cell disorders and chronic intravascular hemolysis are associated with low plasma heparin cofactor II
55. Sickle cell disease: Relation between procoagulant activity of red blood cells from different phenotypes and in vivo blood coagulation activation
56. Fetal hemoglobin in sickle cell disease: Relationship to erythrocyte phosphatidylserine exposure and coagulation activation
57. Antiphospholipid antibodies and thrombosis
58. Antiphospholipid antibodies in homozygous sickle cell disease
59. Antiphospholipid antibodies in sickle cell disease
60. Antiphospholipid antibodies lupus anticoagulant; anticardiolipin and antiphospholipid isotypes in patients with sickle cell disease
61. Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythromatosus
62. Comparison of the primary and secondary antiphospholipid syndrome: A European multicenter study of 114 patients
63. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - A crucial role for acquired free protein S deficiency
64. Thrombosis in sickle cell disease
65. 2-glycoprotein I, a major target antigen of antiphospholipid antibodies
66. Activated protein C resistance in homozygous sickle cell disease
67. Thrombogenic mechanisms of antiphospholipid antibodies
68. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease
69. Tissue factor expression by endothelial cells in sickle cell anemia
70. Sickle cell anemia, right atrial thrombosis and the antiphospholipid antibody
71. Adherence of phosphatidylserine-exposing erythrocytes to endothelial matrix thrombospondin
72. The tissue factor pathway of blood coagulation
73. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral monocytes
74. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease
75. Is there an acute phase response in steady state sickle cell disease?
76. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
77. Circulating activated endothelial cells in sickle cell disease
78. Platelet function and survival in sickle cell disease
79. Abnormalities of platelet aggregation in the vaso-occlusive crisis of sickle cell anemia
80. Elevated platelet count and megathrombocyte number in sickle cell anemia
81. Platelet function in sickle cell anemia
82. Circulating platelet aggregates in sickle cell disease patients with and without vaso-occlusion
83. Platelet hyperactivity in sickle cell disease: A consequence of hyposplenism
84. Abnormalities of platelet aggregation in sickle cell disease
85. Significance of plasma beta-thromboglobulin values in patients with sickle cell disease
86. Platelet activation during pain crisis in sickle cell anemia patients
87. A study of β-thromboglobulin and platelet factor 4 in steady state sickle cell patients
88. Study of platelet function in patients with sickle cell anemia during steady state and vaso-occlusive crisis
89. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease
90. Platelet function in sickle cell disease during steady state
91. Platelet activation and procoagulant activity in sickle cell disease
92. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell disease
93. Platelet regulatory prostanoids and release products in sickle cell disease
94. Sickle cell vaso-occlusive crisis is associated with abnormalities in the ratio of vasoconstrictor to vasodilator prostanoids
95. 2 agonist U46619
96. Elevated urinary levels of thromboxane and prostacyclin metabolites in sickle cell disease reflects activated platelets in the circulation
97. Hemostatic alterations accompanying sickle cell pain crises
98. A double-blind trial of ticlopidine in sickle cell disease
99. Studies of the kallikrein-kinin system in patients with sickle cell disease
100. Reduced plasma kininogen concentration during sickle cell crisis
101. Reduction of contact factors in sickle cell disease
102. Defective release of tissue plasminogen activator in patients with sickle cell anemia
103. Coagulation and fibrinolysis in sickle cell disease
104. Tissue type plasminogen activator antigen and activity in sickle cell disease
105. Regulation of tissue plasminogen activator in sickle cell anemia
106. Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease
107. Factor V Leiden is not responsible for stroke in patients with sickling disorders and is uncommon in African-Americans with sickle cell disease
108. Protein C and protein S in homozygous sickle cell disease: Does hepatic dysfunction contribute to low levels?
109. Demonstration of endothelial adhesion of sickle cells in vivo: A distinct role for deformable sickle cell discocytes
110. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: Pathophysiologic implications
111. In vivo demonstration of red cell-endothelial interactions, sickling and altered microvascular response to oxygen in the sickle transgenic mouse
112. Anti-adhesion therapy in sickle cell disease
113. Ancrod in sickle cell crisis
114. Thrombosis in sickle cell pain crises? Controlled trial of ancrod (arvin) in young adults
115. Trial of low dose aspirin as prophylaxis in sickle cell disease
116. Low intensity oral anticoagulation in sickle cell disease
117. Long-term anticoagulation in sickle cell disease
118. Cerebral vascular disease accompanying sickle cell anemia
119. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents
120. Periodic transfusions for sickle cell anemia and CNS infarction
121. Effect of transfusion therapy on arterio-graphic abnormalities and on recurrence of stroke in sickle cell disease
122. Large vessel occlusion in sickle cell disease: Pathogenesis, clinical consequences and therapeutic implications
123. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography
124. Increased RBC phosphatidylserine exposure in sickle cell disease patients at risk for stroke by transcranial doppler screening
125. Phosphatidylserine in the outer leaflet of red blood cells from β-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes
126. Membrane phospholipid asymmetry in human thalassemia
127. Comparison of the procoagulant activity of red blood cells from patients with homozygous sickle cell disease and β-thalassemia
128. A chronic hypercoagulable state in patients with β-thalassemia major is already present in childhood
129. Abnormal platelet function in β-thalassemia
130. Platelet survival in patients with β-thalassemia
131. In vivo platelet activation in β-thalassemia major reflected by increased platelet thromboxane urinary metabolites
132. PADGEM/GMP140 expression on platelet membrane from homozygous β-thalassemia patients
133. Significance of blood coagulation and platelet profiles in relation to pulmonary thrombosis in β-thalassemia/HbE
134. Thromboembolic events in β-thalassemia major: An Italian multi-center study
135. Thrombotic risk in thalassemic patients
136. Vascular-bed specific hemostasis and hypercoagulable states
137. Sickle cell disease - New treatments, new questions